<link rel='stylesheet' href='https//fonts.googleapis.com/css?family=Roboto:400,500,700,400italic|Material+Icons'>
Open Search
VSTM
Verastem
$
()


  • Verastem reports Q4 adjusted EPS ($1.10), consensus (62c)

    3/14/2024 - 16:26pm
  • Verastem receives Orphan Drug Designation from FDA for avutometinib

    3/5/2024 - 17:29pm
  • Verastem treatment of low grade serous ovarian cancer granted orphan designation

    3/5/2024 - 08:53am
  • Verastem granted fast track designation for Avutometinib+Sotorasib in NSCLC

    1/18/2024 - 16:02pm
  • B. Riley sees these two biotech stocks outperforming in 2024

    12/27/2023 - 07:58am
  • Verastem selects GFH375/VS-7375 as lead program of pact with GenFleet

    12/18/2023 - 07:11am
  • Verastem initiates RAMP 301 trial

    12/13/2023 - 07:27am
  • Verastem assumed with a Buy at BTIG

    11/21/2023 - 06:00am
  • Verastem price target lowered to $34 from $39 at Truist

    11/15/2023 - 07:11am
  • Verastem files $300M mixed securities shelf

    11/8/2023 - 17:03pm
  • Verastem reports Q3 adjusted EPS (71c), consensus (84c)

    11/8/2023 - 16:19pm
  • Verastem announces results from avutometinib, defactinib trial at IGCS 2023

    11/6/2023 - 07:06am
  • Verastem announces initial results of RAMP 203 trial of avutometinib, LUMAKRAS

    10/15/2023 - 06:45am
  • Verastem presents avutometinib and defactinib combination program updates

    9/28/2023 - 14:17pm
  • Verastem initiated with a Buy at B. Riley

    9/26/2023 - 20:46pm
dynamic_feed Breaking News